

Reference: FOI.ICB-2526/091

Subject: Atopic Dermatitis

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION						RESPONSE						
1) Do you use a prior approval to approval funding for atopic dermatitis biologics in adults?						Yes, currently for North Bristol NHS Trust (NBT).						
2) Do you use Blueteq for this prior approval system? If not, which system do you use?						Yes						
3) Please could you tell me how many initiations were approved for the following medicines for atopic dermatitis in your ICB. Please could this information be given as a count for each month over the last year. For clarity, I've included a table to show the requested format. a. Dupilimab b. Baricitinib c. Abrocitinib d. Tralokinumab e. Upadacitinib f. Lebrikizumab												
	Jun-24	Jul-24	Aug-24	Sep-24	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25	May-25
Dupilimab	7	3	2	2	9	10	1	4	4	6	9	2

Baricitinib	0	0	0	0	0	0	0	0	0	0	0	0	
Abrocitinib	0	0	0	0	0	0	0	0	0	0	0	1	
Tralokinumab	1	0	0	0	2	0	1	0	1	1	0	1	
Upadacitinib	0	0	1	0	0	0	2	1	0	2	0	1	
Lebrikizumab	0	0	0	0	0	0	0	0	0	0	0	3	

The information provided in this response is accurate as of 1 July 2025 and has been approved for release by Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.